99 related articles for article (PubMed ID: 20137674)
1. [Effect of hyperprolactinemia upon clinical symptoms of patients with polycystic ovary syndrome].
Wang Y; Hu ZP; Li MZ; Li R; Wang LN; Chen XN; Yang CS; Qiao J
Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2599-603. PubMed ID: 20137674
[TBL] [Abstract][Full Text] [Related]
2. [Interrelationship of abnormal family history in the first degree relatives and clinical phenotype of patients with polycystic ovary syndrome].
Wang Y; Mao WW; Chen YJ; Li MZ; Qiao J; Wang LN
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):756-60. PubMed ID: 18307903
[TBL] [Abstract][Full Text] [Related]
3. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
4. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
Liu ZA; Xue YM; Chen LX; Cai Q; Chen H; Zhang J; Cui QH; Ge J; Yuan T
Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):586-90. PubMed ID: 15498183
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between single nucleotide polymorphism-56 of calpain-10 gene and glucose and lipid metabolism in polycystic ovary syndrome patients].
Diao XH; Shi YH; Gao Q; Wang LC; Tang R; Chen ZJ
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):106-9. PubMed ID: 18683748
[TBL] [Abstract][Full Text] [Related]
7. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
8. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
10. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
11. Clinical and metabolic characteristics of polycystic ovary syndrome without polycystic ovary: a pilot study on Chinese women.
Shi Y; Gao X; Sun X; Zhang P; Chen Z
Fertil Steril; 2008 Oct; 90(4):1139-43. PubMed ID: 17889857
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia.
Hahn S; Tan S; Elsenbruch S; Quadbeck B; Herrmann BL; Mann K; Janssen OE
Horm Metab Res; 2005 Jul; 37(7):438-44. PubMed ID: 16034717
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
[TBL] [Abstract][Full Text] [Related]
14. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ersoy R; Karakoç A; Yetkin I; Ayvaz G; Cakir N; Arslan M
Hum Reprod; 2005 Sep; 20(9):2414-20. PubMed ID: 15890734
[TBL] [Abstract][Full Text] [Related]
15. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
16. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
17. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome.
Nardo LG; Yates AP; Roberts SA; Pemberton P; Laing I
Hum Reprod; 2009 Nov; 24(11):2917-23. PubMed ID: 19617605
[TBL] [Abstract][Full Text] [Related]
18. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
19. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
20. [Study on the relationship between serum adiponectin and insulin resistance in women with polycystic ovary syndrome].
Yang XF; Ren FR; Guo SP
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):261-3. PubMed ID: 16759463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
